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ABSTRACT 
 
         The aim of this study was to compare the efficacies of 
systemic and mucosal immune responses to comparative protective 
preparations from Pasteurella multocida administered to rabbits 
and cattle. 
         Rabbits groups were immunization intranasally and 
subcutaneously with a bacterin, cell lysate and toxoid prepared from 
cultures of P. multocida serotype B: 6, while cattle groups were 
immunized intranasally and subcutaneously with the heamorrhagic 
septiceamia bacterin only. A mixture of freund incomplete adjuvant 
and pea-nut oil was used as an adjuvant to deliver the vaccine 
preparationfrom P. multocida.  
         Subcutaneous immunization of rabbit groups with the 
bacterin, cell lysate and toxin of P. multocida serotype B: 6 induced 
protection in rabbits. The protection was demonstrated in serum 
samples collected from immunized animals and examined for 
antibody titer by the indirect haemagglutination test IHA. The 
highest titers were obtained in the group that received the bacterin 
vaccine and the lowest titers were shown the group vaccinated with 
the cell lysate. Protection of immunized rabbits was further proved 
by challenge inoculation of the animals with viable P. multocida. 
The survival rate in all groups vaccinated subcutaneously was 
100%. 
         Mucosal protection in rabbit groups immunized intranasally 
with the three vaccine preparation was measured by the indirect 
heamagglution testing of nasal lavages and ultimately by challenge 
exposure to viable P. multocida. Results of the IHA showed that the 
 xi
highest titers were recorded in the bacterin-vaccinated group. 
Challenge inoculation in these groups revealed a 100% protection 
only in the bacterin-vaccinated group. 
         Cattle groups were immunized with a bacterin vaccine to 
group cattle via the subcutaneous and intranasal routes. The level of 
the antibody immune response in these two groups and a control 
group that received the bacterin vaccine without the adjuvant was 
measured by the IHA. Similar levels of protection were obtained in 
cattle groups vaccinated subcutaneously with two different bacterin 
doses. The mucosal level of antibodies in the intranasally 
vaccinated group was less compared to subcutaneously vaccinated 
cattle.  
         This study concluded that intranasal immunization of rabbits 
and cattle with P. multocida preparations induced a protective 
immune response against P. multocida. 
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 ﺍﻷﺠﺴﺎﻡﻤﺴﺘﻭﻱ  .ﻤﺘﺸﺎﺒﻪ ﺤﻤﺎﻴﺔ ﻤﺴﺘﻭﻱ ﺃﻋﻁﻲ ﺍﻟﺠﻠﺩ ﺘﺤﺕ ﻁﺭﻴﻕ ﻋﻥ ﺍﻟﺩﻤﻭﻱ ﺍﻟﺘﺴﻤﻡ
 ﻤﻊ ﻤﺠﻤﻭﻋﺔ  ﻤﻘﺎﺭﻨﺘﻪ ﺍﻗل ﻋﻨﺩﺍﻷﻨﻑ ﺍﻟﻤﺤﺼﻨﺔ ﺩﺍﺨل ﺍﻷﺒﻘﺎﺭ  ﻤﺠﻤﻭﻋﺔﻓﻲﺍﻟﻤﻀﺎﺩﺓ 
 . ﺍﻟﻤﺤﺼﻨﺔ ﻋﻥ ﻁﺭﻴﻕ ﺘﺤﺕ ﺍﻟﺠﻠﺩﺍﻷﺒﻘﺎﺭ
 ﺍﻷﺭﺍﻨﺏ ﻭ ﺍﻷﺒﻘﺎﺭ ﻤﺠﻤﻭﻋﺎﺕ ﻓﻲ ﺍﻷﻨﻑ ﺍﻟﺘﺤﺼﻴﻥ ﺩﺍﺨل ﺇﻥ  ﺇﻟﻲﺍﻟﺩﺭﺍﺴﺔ  ﺨﻠﺼﺕ         
 ﻀﺩ  ﺍﺴﺘﺠﺎﺒﺔ ﻤﻨﺎﻋﻴﺔﻌﻁﻲﺘ ﺍﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘل ﺒﺎﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻟﻤﻌﺩﺓ ﻤﻥ ﺒﻜﺘﺭﻴﺎ
  . ﻤﺘﻌﺩﺩﺓ ﺍﻟﻘﺘلﺒﺎﻟﺒﺎﺴﺘﻴﻭﺭﻴﻼﺒﻜﺘﻴﺭﻴﺎ 
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CHAPTER ONE 
INTRODUCTION 
 
           Haemorrhagic septicaemia (HS) is a peracute, contagious and 
highly fatal septicaemic disease of cattle endemic nature in Asia and 
Africa (Bain, 1957). P. multocida is the primary causative agent of 
(HS) in cattle and buffaloes, (Thomson et al., 1975). Under stresses, 
such as shipping and experimental handling, various serotypes of P. 
multocida may replicate rapidly,  causing diseases such as pneumonia, 
conjunctivitis, and septicaemia (Flatt, 1974), and atrophic rhinitis 
(DiGiacomo, 1989). The pathogen is highly contagious and is readily 
transmitted through direct physical and aerosol contact (DiGiacomo, 
1987), making eradication difficult.         
          The serotypes causing HS in Sudan serotypes B: 6 and E: 6 were 
isolated and identified from cases of HS in cattle by (Shigidi and 
Mustafa, 1979). The disease was reported in camels by (Hassan and 
Mustafa, 1985) and serotype B: 6 was identified as the causative agent 
of the disease.  Economic impact of HS is firmly rooted in many 
African and Asian countries with regular sporadic or massive seasonal 
outbreaks resulting in losses. HS as a killing disease has become the 
most serious disease of livestock.         
 Antibiotics have been only partially successful in controlling 
infection, since they do not completely eliminate the bacterium 
(Jaslow, 1981) and, like many other bacteria, P. multocida has 
developed resistance to some of the commonly used antibiotics (Watts, 
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1994). Moreover, antibiotics are only a temporary solution to the 
problem because infection usually recurs within a short period of time 
following treatment (Gaertner, 1991). Another potential means to 
control pasteurellosis is through vaccination. In the Sudan HS in 
controlled by vaccination with a bacterin grown in afermenter under 
the optimizal physical growth conditions,(temperature 37.5ºC, pH 7.4 
and stirring 300 rpm) determinated by Elbashir, (1993). 
         Since P. multocida infections a primary occurs  in the upper 
respiratory tract, the mucosal immune response is likely to be an 
important defense mechanism. Secretory IgA (S-IgA) antibodies are 
abundant in mucosal secretions and function to inhibit microbial 
adherence to epithelial cells (Mestecky, 1987). S-IgA is preferentially 
induced following mucosal immunization ; thus, the production of S-
IgA following intranasal (I.N) vaccination could help to prevent 
bacterial colonization and subsequent infection. 
         The objectives of this study were:  
(i) to evaluate the efficacy of  intranasal (I/N) versus 
subcutaneous (S/C) administration of the vaccines 
in stimulating protective immunity against P. 
multocida infection, following vaccination of 
rabbits and cattle with  a bacterin, cell lysate and 
toxoid preparation from P. multocida.  
(ii) to test the safety of Nigella sativa oil, a mixture 
pea-nut oil and Freund’s incomplete adjuvant as 
mucosal adjuvants for delivery of P. multocida 
vaccine preparations.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
 
2.1. Taxonomy of P. multocida 
         Pasteurella(P.) multocida belongs to the family Pasteurellaceae 
which contains the genera Pasteurella, Actinobacillus, Gallibacteria, 
Haemophilus, Lonepinella, Mannheimia, and Phocoenobacter. These 
genera share a number of common features and some organisms have 
been reclassified within these genera following deoxyribonucleic acid 
hybridization studies and 16S rRNA sequencing Quinn, et al., (2002), 
Hirsh, Maclachan and Walker, (2004). 
 
2.2. Morphology and cultural characteristics 
         P. multocida was described as gram-negative, non motile, 
encapsulated and facultative anaerobic bacteria. The cells are usually 
coccobacillary or short rods in cultures from sick animal tissues and 
show bipolar appearance in smears stained by Leishman and Geimsa 
stains, whereas strains of P. multocida from apparently healthy 
animals were often pleomorphic with occasional short filaments 
Carter, (1957). The capsule of P. multocida type A is made of 
hyaluronic acid, type D capsule is of heparin and the capsule of type F 
is made of chondroitin, Hirsh, et al., (2004). 
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2.3. Biotypes of P. multocida 
         Five biovars of P. multocida were proposed by Carter, (1967) 
designated as biovar a (the mucoid  biovar), biovar  b (the 
haemorrhagic septicaemia biovar), biovar c (the porcine biovar),  
biovar d (the feline biovar) based upon hyaluronidase decapsulation, 
acriflavine folliculation, colonial iridescence, fermentation pattern, 
mouse pathogenicity, host predilection and serologic and immunologic 
characteristic. The fifth biovar is designated E (deer biovar) on the 
bases of its acid reactions in trehalose, sorbitol and mannitol and their 
failure to produce hydrogen sulphate  Frederiksen, (1973).    
 
2.4. Antigenic structure of P. multocida 
         Twenty eight heat-labile and 9 heat-stable antigenic components 
from disintegrated serotype A P. multocida from rabbits were 
demonstrated by electrophoretic analysis Stepkowskii and Zarzycki, 
(1986). Lipopolysaccharide (LPS) comprised the major component 
that resulted from chemical or physical treatment of P. multocida to 
identify their antigenic structure.  
 
2.5. Serotypes of P. multocida 
         Different methods employing a wide range of antigenic 
components and cellular fractions were adopted to serotype P. 
multocida. Roberts, (1947) classified strains of  P. multocida into 4 
serological types I, II, III and IV by the passive mouse protection tests 
in which mice were passively immunized by antisera prepared against 
one strain and counter challenged by the homologous or heterologous 
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virulent cultures of the strain. 
         The colonial morphology and antigenic behavior of variants of  
P. multocida employing the S, R and M designation of Carter, (1957), 
using the acriflavine test revealed a characteristic reaction when 
freshly isolated type D P. multocida were subjected to the test. The test 
rapidly identified the non-immunogenic cultures of P. multocida 
together with the untypable ones. In 1955, Carter described a 
haemagglutination test for identifying P. multocida utilizing specific 
capsular antigens and capsular hyaluronic acid extracted by heating the 
cells at 56°C for 30 minutes in normal saline. These were adsorbed to 
human group (O) erythrocytes and positive results were detected by 
visible agglutination. The test recognized four different serological 
groups designated A, B, C and D and failed to allocate non 
encapsulated cultures to any specific group. When compared to 
Roberts type I, II, III & IV they were found to be identical to type B, 
A, C and D respectively. Carter, (1967) identified a strain of P. 
multocida isolated from cattle with an acute septicaemic disease which 
was different from that caused by serotype B P. multocida in cattle and 
buffaloes and designated it as serotype E. His serotype C gave 
inconclusive results in further studies and was dropped as a distinct 
serological group. Rimler and Rhoades, (1986) identified an additional 
capsular serogroup designated serogroup F among  P. multocida 
isolates from turkeys in USA with somatic serogroups 1, 3, 7 and 12. 
         Namioka and Murata (1961) studied the antigenic relationships 
between the somatic antigens (O-Ag) of P. multocida prepared by 
treating cultures of the organism with normal hydrochloric acid (N-
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HCL) and divided them into common and specific antigens. Cultures 
of type A and D were divided into two groups according to their O-Ag. 
Subculturing of the organisms did not change the O-Ag into the rough 
form even if it was repeated for a year or more. They distinguished 6 
somatic groups (1-6) among 24 strains of P. multocida from different 
parts of the world by means of absorption tests and consequently 6 
serotypes were specified by combining their capsular types and 
somatic groups. On studying 156 cultures of P. multocida obtained 
from different countries, two years later Namioka and Bruner, (1963), 
demonstrated 10 somatic groups designated 1, 2, 3, 4, 5, 6, 7, 8, 9 and 
10 identified 12 serotypes when they were correlated to Carter´s 
capsular types ; 5 O-groups (1, 3, 5, 7 and 9) being distinguished 
among cultures of type A, an other 5 O-groups (1, 2, 3, 4 and 10) 
among type D and a single O-group (6) in type B. A highly pathogenic 
strain of P. multocida (strain P-1059) identified as group 8 was not 
found to be identical with other group 8 strain (strain 147) and it was 
then represented as 8b and the later as 8a. Strain Bunia 11 of Carter’s 
serotype E that was recovered from cattle with HS in Congo belonged 
to O-group 6 as did the serotype E strain of Carter that came from 
Chad. 
         Namioka's agglutination test and Heddlestons gel diffusion 
precipitin test employed by Shigidi and Mustafa, (1980) to study the 
serological inter-relationships of 24 strains of P. multocida represented 
by 11 strains, each representing a different serogroup, and 13 strains 
from cattle with HS agreed in their results indicating that both tests 
were probably employing the same antigen.  
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2.6. Pathogenicity of P. multocida 
         Haemorrhagic septicaemia (HS) of cattle and buffaloes was 
reported in Africa, Asia, the Middle East and Southern Europe and it 
appeared in the form of shipping fever in the Western hemisphere 
Bain, (1963); Geering, (1984). HS of cattle was particularly associated 
with water courses, deltas and wet farming areas, besides, it could also 
occur in dry areas in some countries Geering, (1984). Beef cattle 
grazing effluent irrigated pastures during wet summer months with 
excessive rain fall and unusual cold weather in the preceding month 
experienced a severe outbreak of HS and the young animals were the 
most affected. The animals manifested the acute form of the disease 
with pyrexia, tachycardia and bradycardia, excessive salivation, 
extreme pallor of the mucous membranes and some animals showed 
submandibular and facial oedema and bilateral corneal opacity 
together with the enlargement of the parotid and submandibular lymph 
nodes as well as meningitis which was almost a constant feature 
among all affected animals Lane, et al., (1992). In addition there might 
be development of warm painful swelling about the throat, dewlap, 
briskets or perineum with submucosal petechiae Krishna and Kaushik, 
(1965). Francis, et al., (1980) recorded high fever, depression, 
anorexia, increased pulse and respiratory rates, serous nasal discharge 
and excessive salivation in cattle infected with type E P. multocida in 
Zimbabwe. Septicaemic pasteurellosis was found responsible for 
heavy losses chiefly in low-lying areas of Southern Asia when animals 
were exposed to wet and chilly weather or exhausted by heavy work 
Bain, (1963).   
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         The organisms were isolated as primary etiological factors of the 
disease Carter, (1957); Martinez. et  al., (1987),  
         Camel pasteurellosis was reported by Hassan and Mustafa, 
(1985), who isolated P. multocida organisms from the blood, exudates 
and lyphatics of affected camels. Bain (1963) enlisted septicaemic 
camel pasteurellosis in his report that described the prevalence of the 
disease in Southern Asia. Serotype B P. multocida which was virulent 
to rabbits and calves was primarily isolated from camels that had died 
of an acute disease in Sudan Hassan and Mustafa, (1985). 
         Sheep pneumonia due to P. multocida was distinguished and the 
organisms were principally demonstrated from sheep Kadymov et  al. 
(1987).  
         Fowl cholera, a septicaemic disease of avian species, was 
reported to be predominantly caused by P. multocida serotype A 
Carter, (1959). Four capsular serotype (A, B, D and F) were 
distinguished among avian strains of P. multocida isolated in the USA 
Rimler and Rhoades, (1986).  
2.6.1. Pathophysiology:  
Local: P multocida infection most commonly presents as an infection 
complicating an animal bite or injury. Complications include rapidly progressive 
cellulitis, abscesses, tenosynovitis, osteomyelitis, and septic arthritis. The latter 
two are particularly likely in cat bites because of the small, sharp, penetrative 
characteristics of feline teeth.  
Respiratory: P multocida causes upper respiratory tract infections, including 
sinusitis. It also rarely causes lower respiratory tract infections (primarily in 
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patients with underlying pulmonary disease), including pneumonia, lung abscess, 
and empyema.  
Cardiovascular: P multocida may cause endocarditis, myocardium 
arrthymia, vascular graft infections, central venous catheter infections, 
and pericarditis.  
Central nervous system: P multocida is an uncommon cause of 
meningitis, subdural empyema, and brain abscess. P multocida 
meningitis has been related to cat licks or bites. These diseases 
typically occur in persons at the extremes of age.  
Gastrointestinal: P multocida rarely causes gastrointestinal problems. 
Such problems may include appendicitis, hepatosplenic abscesses, 
renal abscesses, and peritonitis. Patients with peritoneal dialysis-
catheter–related peritonitis have been reported.  
Ocular: Periocular abscess, conjunctivitis, corneal ulcers, and 
endophthalmitis have been reported.  
Genitourinary tract: Pyelonephritis, renal abscess, epididymitis, and 
cervicitis are reported rarely, Thomas, (2006). 
2.7. Disease 
2.7.1. Pasteurellosis 
         Pasteurellosis is a common name of the different diseases of 
domestic and wild animals which is caused by or associated with 
different members of the genus Pasteurella Carter and Bain, (1960). 
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The disease was first described by Bolliger, (1878) in cattle, followed 
by Pasteur, (1880) who described the fowl cholera causative agent, and 
Kitt, (1885) who isolated the organism from septicaemia outbreaks in 
different animals. Hueppe, (1886) proposed the collective name for 
these similar diseases as haemorrhagic septicaemia. Some diseases 
caused by P. multocida shall be mentioned here. P. multocida has a 
commensal existence in the upper respiratory and digestive tract of 
healthy animals and is a frequent secondary invader or opportunist in a 
number of pathogenic processes. 
P. multocida is a primary causative agent of fowl cholera and 
haemorrhagic septicaemia (HS) in cattle and buffaloes or secondary 
invader in pneumonia of cattle, Thomson, et  al., (1975), swine, sheep, 
goat and other species as well as its frequent involvement in bovine 
shipping fever and enzootic pneumonia of pigs. In addition to these 
diseases, the organism was recovered from a wide range of sporadic 
infections in many species and was said to be one of the causes of the 
snuffles in rabbits and severe mastitis of sheep and cattle. Dogs, cats 
and other species frequently harbour the organism in their mouths as 
commensal, Smith, (1955) and consequently man and animal may be 
infected from their bites Bailie, et al., (1978). P. multocida is 
considered also as opportunist or secondary invader in internal 
infection in human Hubbert and Rosen, (1970) 
 
2.7.2. Haemorrhagic septicaemia (HS) 
        Haemorrhagic septicaemia (HS) is a peracute, contagious and 
highly fatal septicaemic disease of both wild and domestic animals, 
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with endemic nature in most parts of tropical and subtropical Asia and 
Africa Bain, (1957). Haemorrhagic septicaemia has been defined as a 
special kind of primary pasteurellosis, Bain, (1954). HS is caused by 
P. multocida serotypes B: 6 and E:6 Banerji, (1953). Serotype B:6 is 
the causative agent of the disease in Asia, while serotype E: 2 was 
recovered from the disease only in Africa Carter, (1984). Few African 
countries, notably Egypt and Sudan, have reported both serotypes, 
Shigidi and Mustafa, (1979).  
 
2.7.2.1. Geographical distribution 
         Haemorrhagic septicaemia (HS) has a worldwide distribution and 
is almost endemic in the African and Asian continents. In Africa it was 
reported in most countries Annosa, et  al., (1975). The disease was 
found across Asia from the middle east region to south eastern Asian 
countries including Indonesia and Philippines Anonymous, (1979). 
Japan was free from the disease since 1954, Carter, (1984). No 
confirmatory reports exist on the presence of the disease in Europe 
with the exception of Italy, east European countries and one sporadic 
case of haemorrhagic septicaemia in fallow deer in the United 
Kingdom Johnes and Hussaini, (1982). The disease was reported in the 
United States Carter, (1982). The disease has not been reported in 
Australia and Canada Bain, (1963). HS which is sometimes mixed 
with pneumonic  pasteurellosis of cattle, is of great significance in 
Mexico, central American countries including Costa Rica, Guatemala 
and south America Carter and De Alwis, (1989). 
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2.7.2.2. Economical importance 
         Haemorrhagic septicaemia is firmly rooted in many African and 
Asian countries with regular sporadic or massive seasonal outbreaks 
resulting in tremendous losses. Haemorrhagic septicaemia as a killing 
disease has become the most serious disease of livestock. Great losses 
in buffaloes which is a species of vital importance in the rural 
economy of Asian region, and cattle in many countries were reported 
Bain, (1963). The estimated losses were ranging between 20-98%. In 
thailand 10,000 annual deaths were reported, mostly useful draft and 
milk producer buffaloes. In India the annual losses ranged between 
30,000-50,000 deaths in cattle. In Sri Lanka the annual losses in 
buffaloes were estimated to be about 15.23% and in cattle about 8.6% 
De Alwis, (1981) the estimated annual losses in this region were 
reported to be 90 million Rupees De Alwis, and Vipulasiri, (1980). 
Heavy losses in cattle with high mortality rate was also reported in 
Zambia,  Francis et  al., (1980). 
 
2.7.2.3. Epidemiology 
         Multi-integrated factors were believed to govern the incidence of 
haemorrhagic septicaemia. A definite interaction of clinical, 
immunological and epizootiological factors with the disease pattern, 
De Alwis, (1984). 
2.7.2.3.1. Host 
         A wide spectrum of wild and domestic animal species were 
susceptible to HS. Cattle and buffaloes Bain, (1963). Buffaloes are 
more susceptible than cattle Anonymous, (1933, 1959). The high 
 13
susceptibility of rabbits and mice, and a lesser degree susceptibility of 
guinea pigs, pigeons and horses were confirmed experimentally by 
Bain, (1963). A variable susceptibility of sheep, goats and fowl, 
Anonymous, (1933, 1959). 
 
2.7.2.3.2. Carrier status 
         The healthy animals carrying the pathogen in their nasopharynx 
and tonsils De Alwis, (1990), play a great role in the disease by direct 
contact or through contamination of soil, water and pasture, and hence 
transmission of infection through inhalation or ingestion route. The 
carriers are of great importance in (HS) outbreaks in many countries 
Gupta, (1962). Variation in degrees of carrier and its significance in 
the epidemiology picture of the disease were reported De Alwis, et  al., 
(1986a). 
 
2.7.2.3.3. Naturally acquired immunity 
         This phenomenon was reported in enzootic areas Dhanda, 
(1959). It was assumed that it may be due to the natural exposure of 
the animal to arrested infection or to virulent organisms, and in both 
cases there are no clinical signs of the disease due to the level of 
immunity. The significant role in the epizootiology of (HS) among 
cattle and buffaloes should be considered, Bain, (1954). 
 
2.7.2.3.4. Environmental factors 
         Clear demarkation into wet, humid and dry climate greatly 
contributes to the disease Baba, (1984). The epidemiological studies 
reported by many workers showed the intimate relation of the wet 
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season to HS outbreaks, De Alwis, (1981) 
 
2.7.2.3.5. Predisposing factors 
         Parasitic, viral and bacterial infections, and overworking 
specially in buffaloes, transport, successive change in nutrition, 
management, and temperature with the changing of seasons, and the 
mode of husbandry were reported as predisposing factor, Annosa, and 
Isoun, (1975). 
 
2.7.2.3.6. Other factors 
         In enzootic areas a lower mortality rate among old animals more 
than two years was observed, while in non-enzootic areas animals are 
found to be susceptible, Baba, (1984). Other factors like the animal 
species play an important role, e.g. buffaloes more susceptible than 
cattle, De Alwis, (1981). 
 
2.7.2.4. HS in the Sudan 
         The disease is endemic in Sudan and was reported nearly from 
all parts of the country. The disease was reported in Blue Nile 
Province (1933), Kassala (1939), Northern kordofan (1943), and 
Upper Nile (1947) (Sud. Vet. Serv. 1933, 1939, 1943, and 1947). 
Serotypes B: 6 and E: 6 were isolated and identified from natural cases 
of HS in cattle by Shigidi and Mustafa, (1979).  
The disease was reported as an acute Pasteurellosis in camels in 
the Blue Nile province by Hassan and Mustafa, (1985) and serotype B: 
6 was identified as the causative agent of the disease. Disease 
outbreaks usually occur after of the rainy season. Changes of weather 
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from dry summer which is characterized by poor range conditions to a 
high humid moderate temperature with abundant good pasture during 
the rainy season was believed to be the major stress factors that 
enhances the appearance of the disease.  
 
2.7.2.5. Clinical signs 
         The disease is characterized by rapid course, high fever, 
salivation, conjunctivitis, lacrimation, cessation of rumination and 
dullness followed by sudden death in preacute condition. In acute 
cases dysponea, painfull groans, respiratory distress, oedematous 
swelling in the head-throat-brisket region and fore limbs followed by 
recumbency at later stages were reported by Bastianello, and Jonker, 
(1981).  
Post-mortem lesions most animals succumbing to HS typically show 
swelling of the neck due to severe blood-tinged oedema. There are 
abundant petechial haemorrhages involving many tissues, and 
particularly serosal membranes. The thoracic, pericardial and 
abdominal cavities may contain serosanguinolent fluid. The lungs are 
congested and notably oedematous. These lesions are similar to those 
observed in severe sepsis. 
 
2.7.2.6. Diagnosis of HS 
         A tentative diagnosis is very essential for combating the spread 
of the disease through both treatment of clinically diseased individuals 
and implementation of usual control measures Carter, et al., (1972). 
Clinical diagnosis is possible to conduct on the basis of the individual 
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and herd history, characteristic clinical signs, morbidity and mortality 
patterns, together with the species and age susceptibility. 
 
2.7.2.6.1.  Microscopy: 
         Direct examination of blood smears stained by Gram stain reveal 
small gram-negative, coccobacilli with characteristic bipolar staining. 
 
2.7.2.6.2. Cultural characteristic 
         Colonies P. multocida on blood agar after inocubation for 24 to 
48 hours at 37ºC are round, grayish and some strains produce large 
mucoid colonies. 
 
2.7.2.6.3. Serological tests 
         Numerous serological tests had been described for the detection 
of P. multocida antibodies in naturally immune as well as in 
vaccinated animals. These tests include the tube agglutination test and 
the serum bactericidal test Bain, (1963). The original indirect 
haemagglutination test (IHA) of Carter, (1955) was modified by Carter 
using formalinized human O cells and later by Sawada et al. (1982) 
using glutaraldehyde treated sheep erythrocytes. Recently an enzyme 
linked immuno-sorbent assay (ELISA) for identification of P. 
multocida was developed by Dawkins et al., (1990), a useful 
diagnostic technique was recommended by O.I.E. (1990).   
 
2.7.2.6.4. Agglutination test 
2.7.2.6.4.1. Rapid slide agglutination test (capsular typing) 
         A single colony is mixed with a drop of saline on a slide, a drop 
of antiserum is added, and the slide is warmed gently. A coarse, 
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floccular agglutination appears within 30 seconds. Old cultures may 
give a fine, granular agglutination that takes longer to appear. 
 
2.7.2.6.4.2. Indirect haemagglutination test (capsular typing) 
         This was originally performed using antigen-sensitized human 
type (O) red blood cells (RBCs) Carter, (1955) but more recently 
sheep (RBCs) have been used. The antigen was prepared as follows; 
Bacteria cultured on blood agar and incubated overnight at 37°C. The 
growth was harvested in 3 ml normal saline containing 0.3% formalin. 
This suspension was then heated at 56°C for 30 minutes, centrifuged 
3000 rpm for 15 minutes at 4°C, and the clear supernatant was frozen 
at -20°C. This was used as the antigen extract. Sheep blood was 
collected aseptically into an anticoagulant and centrifuged at 500 rpm 
for 10 minutes. The packed red blood cells (RBCs) were washed three 
times in sterile normal saline. The antigen extract described above was 
used to sensitize the red blood cells (RBCs) or absorbed on to the red 
blood cells (RBCs). This is done by adding 15 volume of the antigen 
extract to the red blood cells (RBCs) and incubating the mixture for 
one hour at 37°C with frequent shaking. The sensitized red blood cells 
(RBCs) are recovered by centrifugation, washed three times in sterile 
normal saline, and made up to a final 1% suspension in normal saline 
Carter, (1955). 
 
2.7.2.6.4.3. Agglutination test (somatic antigen) 
         The somatic 'O' antigen was prepared by a method similar to that 
described previously for the IHA test Namioka and Murata, (1961). A 
6-8 hour test culture was seeded on to casein sucrose yeast (CSY) 
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blood agar and incubated overnight. The growth is harvested in 2-3 ml 
of physiological saline containing 0.3% formalin , and centrifuged at 
3000 rpm for 15 minutes at 4°C (or 1200-1500 rpm for 30-45 minutes 
at room temperature). The deposited bacteria are resuspended in 25 ml 
normal HCl saline (0.85% saline in a normal HCl solution) to give an 
opacity approximately equivalent to Brown's opacity tube No. 6, and 
incubated overnight. The suspension is again centrifuged, the 
supernatant fluid is discarded, and the cell residue is washed three 
times successively in phosphate buffered saline (PBS) at pH 5.0, 6.0 
and 7.0, respectively. Finally, a suspension of the residual cells, 
equivalent to Brown's opacity tube No. 6, is prepared in PBS at pH 
7.0. Any suspensions that autoagglutinate should be discarded.  
Antisera are prepared against whole bacterial cell suspensions of the 
reference strains B:2 (Asian HS), E:2 (African HS) and B: 11 
(Australian 989, non-HS). The agglutination test is carried out on a 
slide and the test antigen is used against the three types of sera. A fine 
granular agglutination indicates a specific somatic agglutination. The 
test carried out against the standard antigens will facilitate reading and 
interpretation. When nonspecific partial agglutination occurs, the test 
is carried out with tenfold dilutions of the serum against the test and 
standard antigens will help to identify somatic antigen. 
 
2.8. Vaccine 
         Vaccine is a product which may be a suspension of living or dead 
cells, or an antigenic fraction of cells, which when injected with or 
without adjuvant enhance the immunity production in the animal ׳s 
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body, Bain, (1954). 
 
2.8.1. Type of vaccines 
2.8.1.1. Killed vaccine 
         The antibody response against killed vaccines depend on the 
method of cultivation, way of preparation and killing, presence of 
adjuvants, degree of antigenic variation, route of administration and 
dose. 
2.8.1.2. Attenuated vaccine 
         The attenuated live vaccines are prepared by passaging the 
organism in non-ordinary host or by growing in unfavourable 
conditions. Attenuation trials of HS vaccine were achieved by passage 
in pigeons. The use of live attenuated Pasteurella organisms as 
vaccine to prevent the disease caused by P. multocida was first tried 
against fowl cholera by Pasteur, (1880) . Recently the attenuated live 
vaccines against fowl cholera were reported by Bierer, (1969). 
 
2.8.1.3. Toxoid vaccine 
         Toxoid vaccine was proved useful against atrophic rhinitis 
caused by or associated with toxigenic strains of P. multocida  Bording 
and Riising, (1986). Kobish and Pennigs (1986) reported a protection 
against atrophic rhinitis by vaccination with P. multocida toxin. 
 
2.8.1.4. Other vaccine  
         Other types of vaccines were tried in small experimental scale 
with a quite variable degree of protection. Strong immunity was found 
on using germ free filtrate of inflammatory exudates by Gochenour, 
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(1924). 
 
2.9. Vaccination 
         Vaccination is to induce the maturation of cells involved in the 
specific removal of a pathogenic agent and to maintain clones of 
memory cells specific for the target antigens in the circulation and in 
the secondary lymphoid organs. The important contribution of B cells 
as antigen presenting cells to the activation of T cells has been 
reported Ron, et al., (1981). 
In all countries where HS occurs, vaccination is adopted as the 
method of control. A variety of antigen preparations were developed 
and used to confer protection in animals against P. multocida 
infections. These included inactivated whole cell preparations 
(bacterins), life whole cell cultures, aggressins, and extracted cell 
fractions and components. Varying degrees of effectiveness were 
recorded throughout the history of the use of bacterins as immunogens 
against different P. multocida infections in different host species 
Joseph and Hedger, (1984); yet, the use of adjuvants improved the 
immune response to some bacterins Yadav and Ahooja, (1986). The 
fact that P. multocida infections were often associated with other 
precipitating factors had, however, necessitated the use of combined 
vaccines Confer, et al., (1985).  
Aggressins and antisera were used to protect cattle against respiratory 
disease Mosier, et al., (1989). Extracts of bacterial components 
including capsular extracts Nagy and Penn, (1976), LPS and proteins 
Lutenbergh, (1986), saline purified CHO-protein fractions Syuto and 
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Matsomoto, (1982) and chaotropically-extracted antigens e.g. KSCN 
extract Lu, et al., (1987), all had yielded superior beneficial results in 
animals challenged with homologous and sometimes heterologous P. 
multocida organism. 
In Sudan annual vaccination using a bacterin produced by the 
local  Veterinary Research Laboratory, from local bacterial isolates of 
P. multocida serotypea B : 6 and E : 6. The bacterin vaccine was 
produced in fermenter under optimized physical growth conditions, 
temperature 37.5ºC, pH 7.4 and stirring 300 rpm, reported by Elbashir, 
(1993).   
 
2.10. Immunity against P. multocida 
         It is generally believed that, the type of immunity developed 
against P. multocida is mainly antibody mediated. Nagy and Penn 
(1976) reported that antibody level in vaccinated cattle determined by 
passive mouse protection (PMP) test indicated that immunity to HS is 
exclusively antibody mediated. The duration and the magnitude of 
these responses are affected by many factors such as virulence, 
potency of the antigen, the dosage, and the method of induction and 
the age of the animal. 
The mechanism of the protection effect of antibody is shown by 
slowing of the bacterial multiplication with prolongation of the lag 
phase, aided possibly by conglutinin. The previous assumption that the 
major protection mechanisms against HS were due to specific opsonin 
and complement factors was explained by Dawkins et al., (1991). 
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2.10.1. Types of immunity to HS 
         Types of immunity to HS are recognized as naturally acquired, 
artificial active, or passively inducible.  
 
2.10.2. Active natural immunity 
         In endemic areas, however, regular outbreaks occur mostly 
during the wet season, depending on an interaction between a number 
of factors (burden of infection, host defense mechanism, immunity 
level, etc). Some animals succumb to clinical disease while others will 
develop what is described as an arrested infection leading to a 
naturally acquired immunity De Alwis, (1987). Thus in endemic areas, 
the adult population through successive exposures acquire natural 
immunity and only small number of hitherto unexposed animals will 
remain susceptible at each outbreak. It is assumed that morbidity and 
mortality due HS in a given population largely depend on the 
proportion of the immune to non-immune animals and therefore the 
phenomenon of naturally acquired immunity is responsible for the 
different patterns of morbidity and mortality in endemic and non 
endemic areas . 
 
2.10.3. Active artificial immunity (Vaccination) 
         Vaccination is generally accepted as the best mean of control 
against 
Pasteurellosis and vaccines in different forms are readily available 
throughout the world. 
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2.10.4. Passive artificial immunity 
        Mosier et al. (1989) reviewed the evolution of vaccines for 
bovine pneumonic Pasteurellosis, where they stated that, the use of HS 
antisera to induce passive immunity to HS was practiced since 1918. 
The use of HS antisera was found to be of value when given before 
shipment to control shipping fever.  
 
2.11. Mucosal immunity 
         The mucosal surfaces of the gastrointestinal and respiratory tract 
represent the principal portals of entry for most pathogens. Most 
external mucosal surfaces are replete with organized follicles and 
scattered antigen-reactive or sensitized lymphoid elements, including 
B cells, T lymphocytes, T cell subset, plasma cells and a variety of 
other cellular elements involved in the induction and maintenance of 
immune response. The major antibody isotype in external secretions is 
secretory immunoglobulin A (S-IgA). Approximately 40 mg of IgA 
per Kg of body weight is secreted daily, especially from the 
gastrointestinal tract. It is, however, interesting that the major effector 
cells in the mucosal surfaces are not IgA B cells, but T lymphocytes of 
CD4 as well as CD8 phenotypes, it is estimated that T lymphocytes 
may represent up to 80% of the entire mucosal lymphoid cell 
population, Conley, (1987). 
 
2.11.1. Common mucosal immune system 
         The immunologic network operating on external mucosal 
surfaces consists of gut associated lymphoid tissue (GALT), the 
lymphoid structures associated with bronchoepithelium and lower 
 24
respiratory tract (BALT), occular tissue, upper air way, salivary 
glands, tonsils and nasopharynx (NALT), larynx (LALT), middle ear 
cavity, male and female genital tracts, and the mammary glands. The 
organized lymphoid follicles in the GALT and BALT are considered 
the principal inductive sites of mucosal immune response, Staats, 
(1994).  
 
2.11.2. Gut and bronchoepithelium associated lymphoid tissues 
         A substantial body of information has been generated with peters 
patches and  other organized lymphoid follicles in the gut-associated 
lymphoid tissue (GALT), including the appendix Dasso, (1997) and 
the bronchoepithelium associated lymphoid tissue (BALT) concerning 
the induction of mucosal immune responses and the development of 
systemic hypo-responsiveness following oral exposure to an antigen 
(oral tolerance) Javed, (1995). The common features of all inductive 
mucosal sites include an epithelial surface containing M cells, 
overlying organized lymphoid follicles, mucin producing glandular 
cells lymphocytes, plasma cells, dendritic cells, and macrophages. The 
mucosal epithelial cells express polymeric immunoglobulin receptor 
(pIgR) and secretory component, major histocompatibility complex 
(MHC), class 1 and 11 molecules, other adhesion molecules, and a 
variety of cytokine and chemokine receptors McGhee, (1999). The 
dendritic cells are present in different components of the common 
mucosal immune system, including the organized lymphoid tissue and 
the mucosal epithelium; these cells can be strongly associated with 
initiation of immune response and promote development of active 
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immunity Liu, (1993). Recent observations have suggested that 
dendritic cells are potent antigen-presenting cells (APC), and are 
critical in initiating primary immune responses, graft rejection, 
autoimmune disease, and generation of T-cell-dependent B-cell 
responses. The APC function is attributed in part to their ability to 
express costimulatory molecules (CD80 and CD86), and other 
accessory ligands necessary for up regulation or induction of tolerance 
Steinbrink, (1997). 
 
2.11.3. Nasopharynx Associated lymphoid Tissue (NALT) 
         Nasopharynx associated lymphoid tissue NALT is well described 
and characterized in small laboratory animals. It is present as paired 
lymphoid aggregates in the floor of the nasal cavity at the entrance to 
the pharyngeal duct. In farm animals, no comparable aggregates are 
found at these sites, but isolated lymphoid nodules (ILF) have been 
described in horses and sheep.  
 
2.11.4. Lymphoid tissues of the Waldeyer’s Ring  
         In contrast to small laboratory rodents, the lymphoid tissues of 
Waldeyer’s ring are well developed in farm animals and humans. 
Therefore, interest has centered on them instead of NALT. Lymphoid 
tissues of Waldeyer’s ring guard the nasal, oral and auditory passages 
into the pharynx. They are formed by large aggregates of lymphoid 
nodules termed tonsils that occur constitutively at distinct anatomical 
sites in the pharynx of each species and ILF that vary in number. In the 
oropharynx, the lingual tonsil, the palatine tonsil and the tonsil of the 
soft palate are present; in the nasopharynx, the pharyngeal and tubal 
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tonsils are present. Tonsils are important for inducing immunity at 
mucosal sites. Some pathogens have, however, developed mechanisms 
to overcome tonsillar defenses and may use them as the port of entry, 
replication and colonization Huang, et .al., (1990). Several pathogens 
are able to persist asymptomatically within the tonsils making the 
identification of carriers difficult in disease control and elimination. 
Therefore, tonsils are highly important tissues for diagnostic 
investigations of infectious diseases. The pharyngeal and tubal tonsils 
are the main targets for nasal vaccines which are attractive, because of 
the relative accessibility and high permeability of tonsils and the 
micro-environmental conditions with less acidic pH, lower levels of 
enzymatic activity and no ruminal digestion  Stanley, et al., (2001). 
Although not widely used, nasal vaccination may provide a practical 
alternative to oral vaccination to induce mucosal immune responses. 
The intranasal inoculation of sheep with Pasteurella hemolytica 
caused a significant increase in the size of BALT, a significant 
increase in numbers of BALT structures and had a protective effect 
against colonization Zamri. et  al., (1999). 
 
2.11.5. Larynx-associated lymphoid tissue (LALT). 
         Some evidence suggests the existence of organized lymphoid 
tissue in the larynx in human, lymphoid aggregates have been 
observed at the laryngeal side of the epiglottis in >80% of infants and 
children younger than 22 months of age. In the follicular areas of the 
aggregates, most cells appears of B lymphocytes, with some CD4 
lymphocytes in the germinal centers, and the inter-follicular areas 
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contain equal numbers of B and T cells. Other investigators have also 
observed scattered lymphocytes in the laryngeal epithelium. It remains 
to be determined whether larynx-associated lymphoid tissue (LALT) is 
a distinct physiologic entity or a pathologic reaction in response to 
local infection or other environmental insults, Tschernig, (1995). 
 
2.11.6. Other mucosal immune systems  
         The tonsils, middle ear cavity, male and female genital tracts, 
mammary glands and salivary glands exhibit similar distribution of 
IgA and IgD immunocytes. In addition, scattered areas in the crypt 
epithelium of nasopharyngeal tonsils express secretary component. 
Another important feature of mucosal lymphoid tissue and the 
follicular germinal center is induction of the J-chain gene in some B 
cell subsets. Tonsillar germinal centers express a very high percentage 
of extra follicular immunocytes with J-chain expression. More than 
90% of these immunocytes are of the IgA isotype Bernstein, (1999). 
 
2.12. Mucosal adjuvants 
         Adjuvants have a complex mechanism of action as 
immunostimulators, delaying the absorption of vaccine and prolonging 
the antigenic stimulus to the antibody forming cells. A number of 
chemical agents have been tested to enhance the immunogenicity of 
mucosally administered antigens including cholera toxin, E. coli-labile 
toxin, actins, low-oil emulsion (MF59), lipid A, lysophosphatidyl 
glycerol and cytokines (IL-5). Such antigens in general induce only 
weak or insufficient immune responses when administered mucosally. 
Adjuvants influence virtually every aspect of immune response to an 
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antigen, Elson, et  al., (1999). 
 
2.12.1. Cholera toxin and E. coli-labile toxin  
        The two toxins have about 80% sequence homology and exhibit 
significant immunologic cross-reactivity. The holotoxin consisting of 
A and B subunits is required for adjuvant effects. Cholera toxin (CT) 
binds to M cells and to the GM1-ganglioside receptors on the mucosal 
epithelium. CT has been shown to enhance the immunogenicity of 
relatively weak mucosal antigens when conjugated or mixed with the 
antigen and delivered via the mucosal route. The adjuvant effects are 
seen on serum IgG and mucosal IgA responses to unrelated antigens 
administered orally at the same time. Either free or conjugated CTB 
subunit (CTB) can act as an adjuvant in intranasal immunization, 
Taylor, (1995). 
 
2.12.2. Vitamin D3  
         It was first demonstrated in mice that an intramuscular, 
subcutaneous or intradermal, Enioutina, et al., (2000), immunization 
with a microbial antigen and aluminum hydroxide as the adjuvant 
induces a mucosal immune response when 1α, 25(OH)2, D3, (vit D3, 
calcitroil), the active metabolite of vit D3 is added as an additionally 
immunomodulator. Mice show enhanced antigen specific IgG and IgA, 
in serum and all tested mucosal secretions (tears, oral, vaginal and 
colorectal secretions), Daynes, et al., (1996).   
 
2.12.3. Avridine 
         A lipoidal amine, functions by facilitating uptake and release of 
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antigens in the macrophages in mucosal tissue, with subsequent 
production of immunoregulating cytokines, Taylor, (1995). 
 
2.12.4. Other adjuvants 
         Other adjuvants may improve mucosal contact with antigens with 
or without enhancement of the release of immunoregulatory, cytokine, 
low-oil emulsion, lipid A and glycerol, Taylor, (1995). 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
3.1. Bacteria 
         Three field isolates of P. multocida (224, 222 and 225) were 
obtained from the freeze-dried stock of the Department of 
Microbiology, Faculty of Veterinary Medicine, University of 
Khartoum. They were originally isolated from outbreaks of bovine 
Haemorrhagic Septicaemia (HS) in Halfa and Nyala. They were 
preserved lyophilized at -20° C. A lyophilized P. multocida serotype 
B: 6 were kindly provided by Central Veterinary Research 
laboratories. Freeze-dried cultures were reconstituted in nutrient broth 
and incubated at 37°C for 24 hours; growth was checked and tested for 
purity and the cultures were kept in slants of blood agar.  
 
3.2. Laboratory animals 
 3.2.1. Rabbits        
          Twenty four rabbits were purchased from the local market in 
Omdurman. Animals were kept at the animal housing of the 
Department and allowed to adapt for 2 weeks. All rabbits were 
prophylactically treated with antibiotic and anthelmintic (Albendazole, 
AVICO). Food and water were supplied and later divided into 
subgroups each of eight rabbits.  
 
3.2.2. Cattle        
         Thirty head of cattle in a traditional farm in White Nile state, all 
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animals were first given prophylactic dose of antibiotic, anthelmintic, 
and they were divided into three equal groups. 
3.3. Sterilization 
3.3.1. Flaming  
         It was used to sterilize wire loops, needles and scalpels. 
 
 
3.3.2. Red heat 
         It was used to sterilize wire loops, points and searing spatulas by 
holding them over bunsen burner flame until became red-hot. 
 
3.3.3. Hot air oven  
         It was used to sterilize glass wares such as test tubes, graduated 
pipettes, flasks, forceps and cotton swabs. The holding period was one 
hour at 160°C. 
 
3.3.4. Moist heat (autoclave) 
         Autoclaving at 121˚C for 15 minutes was used for the 
sterilization of media and plastic wares. Autoclaving at 115ºC for 10 
minutes was used for sterilization of sugar containing media.  
 
3.4. Bacteriological media  
         The media utilized in the study constituted the essential nutrients 
for the growth and maintenance of P. multocida. They were principally 
employed to isolate, modify or to characterize and identify the strains 
of P. multocida. The ingredients incorporated in the media were 
dissolved by heating with constant stirring by aid of a magnetic stirrer. 
NaOH and HCL were used to adjust the pH. Media were checked for 
sterility by overnight incubation at 37oC and for vitality by inoculation 
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of a positive control and unless otherwise stated they were preserved at 
4ºC. 
 
3.4.1. Blood agar  
         It was the main media used to grow P. multocida during the 
study. Forty grams of blood agar base No.2 (oxoid) were suspended in 
1 liter of distilled water, dissolved by boiling, mixed and sterilized. 
The medium was cooled to 50°C and defibrinated sheep blood was 
added aseptically to give final concentration of 10%, mixed gently and 
distributed as 15 ml into sterile Petri dish. The poured plates were 
allowed to solidify at room temperature on flat surface.   
 
3.4.2. Nutrient agar  
        To one liter of nutrient broth (oxoid), 15g agar were added, it was 
dissolved by boiling and sterilized, cooled to bout 50◦C and distributed 
in 15 ml amount per plate. The poured plates were left to solidify at 
room temperature on a leveled surface.  
 
3.4.3. Nutrient broth 
         Thirteen grams of nutrient broth powder (oxoid) were dissolved 
in one liter of distilled water, mixed well, distributed in 3 ml amount 
into clean test tubes and sterilized.  
 
3.4.4. Brain heart infusion broth (Oxoid) 
        One liter of medium was prepared by dissolving 37g of powder 
(conained 12.5 g calf brain infusion solids, 5g beef heart infusion 
solids, 10g proteose peptone, 5g Nacl, 2g Dextrose and 2.5g disodium 
hydrogen phosphate) in one liter of distilled water. The pH was 
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adjusted to 7.4 and the mixture was distributed into Bijou bottles (4ml/ 
bottle) allowed to cool and stored at 4 °C. 
3.5. Solutions 
3.5.1. Phosphate buffer saline (PBS) 
       Constituted of three solutions was mixed to form PBS. These were  
Solution (A) which was prepared by dissolving 16 g NaCl, 0.4 g KCl, 
2.3 g disodium hydrogen phosphate into 1500 ml of deionized distilled 
water. Solution (B) which was prepared by dissolving 0.42 6g 
magnesium chloride hydrous into 200 ml deionized distilled water. 
Solution (C) which was prepared by dissolving 0.264g calcium 
chloride in 200 ml deionized distilled water. 
The three solutions were separately autoclaved at 121°C for 15 
minutes and allowed to cool at room temperature. Solution B was 
aseptically added to solution A followed by solution C and the final 
volume was brought to two liter by the addition of sterile distilled 
water. 
 
3.5.2. Normal saline 
          It was prepared by dissolving 8.5g NaCl in one liter of distilled 
water and autoclaving at 121° C for 15 minutes.   
 
3.5.3. Saturated ammonium sulfate (SAS) 
        A saturated solution of ammonium sulfate (SAS) was made by 
dissolving 760 g of pure ammonium sulfate in one liter of distilled 
water and sterilization at 121°C for 15 minutes. It was then allowed to 
stand at room temperature for several days until used.  
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3.6. Preparation of the vaccine antigens   
         The antigens used in this study were haemorrhagic septicaemia 
vaccine (whole formalin-killed P. multocida serotypes B and E), a cell 
lysate of P. multocida serotype B and toxoid prepared from P. 
multocida culture.   
 
3.6.1. Haemorrhagic septicaemia vaccine  
         It was prepared according to the protocol of vaccine production 
(without adjuvant) in Central Veterinary Research Laboratories 
(Soba). They were all propagated in the Gottingen bioreactor 
(fermenter) under the optimized physical growth conditions, 
temperature 37.5ºC, pH 7.4 and stirring 300 rpm, for vaccine 
production, as a rule, all production steps of vaccine were done under 
strict sterile conditions, determinated by Elbashir, (1993).   
 
 
3.6.2. Preparation of cell lysate  
         P. multocida serotype B:6 was grown in nutrient broth  for 48 
hours at 37°C. 100 ml culture were harvested by centrifugation at 3000 
rpm for 15 minutes at 4°C and the packed cellular mass was washed 
three times with phosphate buffer saline pH 7.0. The cells were then 
resuspended in the same buffer and subjected to ultrasonic disruption 
(Sonnicator) (MSE-England) 18000 rpm for 10 minutes at 4°C 
Mortenson et al., (1962). Cell debris and unbroken cells were removed 
by centrifugation at 3000 rpm for 15 minutes and the supernatant was 
stored frozen until used. 
 
[ 
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3.6.3. Culture of the organism and toxin harvest 
          P. multocida serotype B: 6 was grown on blood agar for 24 
hours at 37°C in candle jar (5-10% C2O). After incubation single 
colonies were used to seed bottles of brain heart infusion broth which 
were incubated at 37°C for 3 days. The broth cultures were removed 
from the incubator and allowed to stand overnight at 4°C the bacterial 
cells settled on the bottom of the bottles during this period, leaving a 
relatively clear supernatant broth, the supernatant were carefully 
decanted into glass centrifuge cups and centrifuged at 3000 rpm for 15 
minutes at 4°C. The supernatant was then filtrated through 0.45 um 
millipore filter, Suleiman, (1995). 
 
3.6.3.1. Partial purification of the toxin 
          The exotoxin was precipitated according to the method of 
Suleiman, (1995), 122 ml of the saturated solution of ammonium 
sulphate (SAS) was added slowly drop-wise to 100 ml of the culture 
filtrate thus effecting a 55% ammonium sulphate saturation of the 
filtrate. The procedures were carried out at room temperature except 
the flask containing the toxin which was immersed in an ice bath 
during the precipitation procedure. After the SAS was added the 
mixture was allowed to stand overnight at 4°C, the precipitate was 
then removed by centrifugation at 5000 rpm at 4°C. It was then 
dissolved in PBS containing 0.02% sodium azide as preservative. The 
final volume was approximately 10 % of original culture, this solution 
was transferred to cellulose dialysis tubing and dialysed for 36 hrs 
against DW at 4°C. Part of the dialysed material containing the 
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partially purified toxin was used to test it’s possible dermonecrotic 
activity while the rest was formalinized (0.3%) and kept at 4°C and 
stored frozen until used. 
 
3.7. Dermonecrotic activity 
       The ability of the crude toxin to induce dermonecrosis in a rabbit 
skin was assayed by inoculation of 100 ul of crude toxin intradermally 
into two rabbits. Acontrol group of two rabbits was inoculated with 
sterile normal saline. Animals were observed for 48 hours for 
development of injection site reactions. 
 
3.8. Preparation of P. multocida toxoid 
         0.3% formaldehyde was added to the partially purified toxin and 
was kept at 4°C.  
 
3.9. Mucosal adjuvants  
      The safety of Nigella sativa seed oil as mucosal adjuvants was 
initially tried in rabbits. Two rabbits were used and each received 100 
and 250 ul subcutaneously of crude oil. 
        Pea-nut oil mixed (1:1 v/v) with Freund’s incomplete adjuvant 
was also experimented as a possible safe mucosal adjuvant in 50 ul per 
animal (rabbits and cattle).  
 
3.10. Immunization of rabbits 
3.10.1. Bacterin vaccine 
         The bacterin was mixed with the mucosal adjuvant and the 
mixture was placed in a water bath at 37°C for 15 minutes. 100 µl of 
the preparation was administered intranasally (3 rabbits) and 
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subcutaneously (3 rabbits) and all rabbits received a booster dose on 
day 24 post initial inoculation. A control group of two rabbits received 
normal saline through the same routes as for the treated groups. 
 
 
3.10.2. Cell lysate 
         The cell lysate was mixed with the mucosal adjuvant and the 
mixture was placed in a water bath at 37°C for 15 minutes. 100 µl of 
the preparation was administered intranasally (3 rabbits) and 
subcutaneously (3 rabbits) and all rabbits received a booster dose on 
day 24 post initial inoculation. A control group of two rabbits received 
normal saline through the same routes as for the treated groups. 
 
3.10.3. Toxoid 
         The toxoid was mixed with the mucosal adjuvant and the mixture 
was placed in a water bath at 37°C for 15 minutes. 100 µl of the 
preparation was administered intranasally (3 rabbits) and 
subcutaneously (3 rabbits) and all rabbits received a booster dose on 
day 24 post initial inoculation. A control group of two rabbits received 
normal saline through the same routes as for the treated groups.   
 
3.11. Samples collection from rabbits 
         Blood was collected from jugular vein; serum was separated and 
stored at -20°C. Nasal washings were obtained by tilting the rabbit’s 
head to one side and infusing 1ml of sterile phosphate buffer saline 
into the nares and collecting drops which were sneezed onto a sterile 
Petri dish, this process was repeated for the other side the fluid 
collected and frozen at-20°C Jarvenin, et al., (1998).  
Blood and nasal washing samples were collected (i) prior to 
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inoculation (days 0), (ii) 1 week following initialed inoculation (7, 14 
and 21), (iii)  1 week after booster dose.   
 
3.12. Challenge inoculation of rabbits 
         Cultivation for viable counts was done on blood agar and viable 
bacteria counts were performed by serial ten fold dilution using the 
Miles and Misra, (1938). Challenge of vaccinated rabbit groups and 
unimmunized control groups was carried out on day 35 post 
vaccination by intranasal administration of dose of 2.5x106 CFU/ml. 
The dose was chosen based on results of a previous study Jarvinen et, 
al., (1998).  
 
3.13. Immunization of cattle 
3.13.1. Group 1 
         The bacterin was mixed with the mucosal adjuvant (1:1 v/v) and 
the mixture was placed in a water bath at 37°C for 15 minutes. 0.5 ml 
of the preparation was administered subcutaneously (8 cattle), cattle 
received a booster dose on day 24 post initial inoculation. A control 
group (2 cattle) received normal saline through the same route as for 
the treatment group. 
 
3.13.2. Group 2 
        A dose of 0.5 ml of the antigen described above was inoculated 
intranasally (8 cattle), the cattle received a booster dose on day 24 after 
post- vaccination. Control group (2 cattle) received normal saline via 
the same route of the treatment group. 
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3.13.3. Group 3 
         This group served as control group, received 1ml of the bacterin 
(Final product), a recommended dose according to Central Veterinary 
Research Laboratories (Soba). The group was vaccinated with the 
bacterin without the mucosal adjuvant. 1ml of the bacterin was 
administered subcutaneously (8 cattle), the cattle received a booster 
dose on day 24 post initial inoculation. A control group (2 cattle) 
received normal saline through the same route as for the treatment 
group. 
 
3.14. Sample collection 
         Blood was collected from jugular vein; serum was removed and 
stored at -20C. Nasal samples were obtained by swabbing both nares 
of cattle and the swabs were immersed in tubes containing phosphate 
buffer saline which was kept at -20°C until processing.  
Blood and nasal swabs samples were collected (i) prior to inoculation 
(days 0), (ii) 1 week following initialed inoculation (7, 14, 21 and 24), 
(iii)  1 week after booster dose.   
 
3.15. Indirect haemagglutination test (IHA) 
         This was originally performed using antigen-sensitized human 
type O red blood cells (RBCs) Carter, (1955), but more recently sheep 
red blood cells (RBCs) have been used Sawada, (1982). The antigen is 
prepared as follows; 
Bacteria cultured on blood agar and incubated overnight at 37°C. The 
growth is harvested in 3 ml normal saline containing 0.3% formalin. 
This suspension is then heated at 56°C for 30 minutes, centrifuged at 
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3000 rpm for 15 minutes at 4°C, and the clear supernatant was stored 
at -20°C. This is used as the antigen extract. Sheep blood was collected 
aseptically into anticoagulant and centrifuged at 500 rpm for 10 
minutes. The packed red blood cells (RBCs) are washed three times in 
sterile normal saline. The antigen extract described above was used to 
sensitize the red blood cells (RBCs) or absorbed on to the red blood 
cells (RBCs). This is done by adding 15 volume of the antigen extract 
to the red blood cells (RBCs) and incubating the mixture for one hour 
at 37°C with frequent shaking. The sensitized red blood cells (RBCs) 
are recovered by centrifugation, washed three times in sterile normal 
saline, and made up to a final 1% suspension in normal saline. 
The test was carried out in microtitre plates, and was performed as 
described by Cho, et al., (1976) as follows: 
1) The extract of the strain was prepared as described above and used 
to sensitize the sheep red blood cells (RBCs). 
2) Using two separate rows of wells the first wells are filled with 180 
ul normal saline followed by 100 ul in the next six wells or more. 
3) The samples of serum and nasal wash were each separately diluted 
in each row by adding 20 ul of the serum to the first well and mixing 
with a pipette. From this well 100 ul were transferred to the next well, 
mixed, and the process carried on until well seven. This constitutes 
1/10 dilution in the first well and a doubling dilution thereafter.  
4) All the wells are each filled with 100 ul of antigen-adsorbed/ 
sensitized red blood cells (RBCs), shaken slightly and left at room 
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temperature.  
By the addition of the sensitized blood, the serum and nasal wash 
dilution in the wells are a doubled, e.g. 1/20 in well one, 1/40 in the 
second, and so on. 
         A positive, negative and saline control are included for each test 
run. 
5) The first reading is taken after two hours and a final reading after 18 
hours. A coarse agglutination of the red blood cells (RBCs) along the 
sides of the concave wells is taken as a positive reading, and the 
formation of a button at the center of the wells as negative. An 
arbitrary score of 1-4 is given depending on the size of the 
agglutination . Indirect haemagglutination test (IHA) can be used for 
typing unknown strains, the test itself is more efficient when dealing 
with serotypes B and E and is more reliable as quantitative tests 
against these strains .  
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CHAPTER FOUR 
RESULTS 
 
 
4.1. Mucosal adjuvant 
         250 and 100 µL of Nigella sativa crude oil injected 
subcutaneously and intranasally resulted in rough coat, lacrimation, 
fever and death occured within 24 hour. Due to the toxicity of Nigella 
sativa crude oil in rabbit Zaoui et al., (2002), it was excluded from 
experimentation as a mucosal adjuvant. 
 Pea-nut oil mixed with Freund incomplete adjuvant (v/v 1:1) 
employed as a possible safe mucosal adjuvant in rabbits proved to be 
safe and hence it was used to deliver the antigens in cattle and rabbits.   
 
4.2. Dermonecrotic activity of the partially purified toxin 
         Filtrated culture supernatants of P. multocida injected 
intradermally in rabbits caused a local inflammation with no 
dermonecrosis that returned to normal three days post injection, (Fig 
5).  
 
4.3. Immune response of rabbits 
4.3.1. Bacterin vaccine          
         Nasal lavage from immunized rabbits and controls were tested 
for mucosal antibody by the indirect heamagglutination test. The 
highest titer (20, 20 and 10), was recorded in samples tested on day 21 
post primary immunization. The antibody titer increased after boosting 
the animals   Results are shown in table 1 fig 1. 
         Results of the indirect haemagglutination test for serum samples 
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of rabbits immunized with bacterin are shown in table 1. The highest 
titer (40, 80, and 40), was obtained in samples taken at day 21 post 
vaccination. The antibody titer doubled after the booster dose. 
 
4.3.2. Cell lysate 
         The indirect heamagglutination test of nasal washes from 
vaccinated rabbits and unvaccinated control group detected mucosal 
antibodies. High titer (10, 20 and 10) was reported in samples taken on 
day 21 and after boosting. Results are shown in table 2 and fig 2. 
         Serum samples from cell lysate inoculated rabbits and controls 
group were tested by the indirect heamagglutination test. The highest 
titers were recorded in samples tested on day 21 post primary 
immunization and after booster dosing (Table 2).  
 
4.3.3. Toxoid 
         The results of the rabbit group nasal lavages taken from 
immunized rabbits and control group and test by the IHA documented 
the presence of mucosal antibodies. The highest titers were recorded in 
samples taken on day 21 (20, 10, and 10). The antibody titer increased 
after booster dose. Results are illustrated, (Table 3 and Fig 3).  
        The highest titers subcutaneously for toxoid vaccinated group of 
rabbits were reported on sera sampled on day 21 and after booster 
inoculation   (table 3).  
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Table (1). Results of indirect haemagglutination test of rabbit groups 
vaccinated with P. multocida bacterin. 
Route of 
administration 
Rabbits
Day 
0 
Day 
7 
Day 
14 
Day 
21 
Day  
24 
Day 
31 
1 0 0 10 20 Booster 40 
1 0 10 10 20 Booster 20 
1 0 0 10 10 Booster 40 Intranasal 
Control 0 0 0 0 
N. 
Saline 
0 
1 0 10 20 40 Booster 80 
1 0 10 20 80 Booster 160 
1 0 0 20 40 Booster 80 Subcutaneous 
Control 0 0 0 0 
N. 
Saline 
0 
0
20
40
60
80
100
120
Ti
te
ra
tio
n
0 7 14 21 31
Days
 FIG (1) Average of IHA of group of rabbits immunization with bacterin
I/N S/C  
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4.4. Challenge exposure of vaccinated rabbits. 
4.4.1. Bacterin   
       The survival rate of intranasally and subcutaneously bacterin 
immunized groups of rabbits was 100% while the entire control group 
succumbed within 24 hour (table 4).                
 
 
4.4.2. Cell lysate  
        67% was the rate of survival for the rabbit group vaccinated 
intranasally with cell lysate. All animals in the control group died after 
24 hr post challenged. All rabbits in the subcutaneous immunized 
group survived the challenged inoculation while the control group died 
within 24 hours, (table 4). 
 
4.4.3. Toxoid 
        Survival rate of rabbits group immunized intranasally with toxoid 
had a 67%. All animals in the control group succumbed within 24 hour 
after challenged. Group of rabbits vaccinated subcutaneously had a 
100% survival rate (table 4). 
 
4.5. Immunization of cattle 
4.5.1. Group 1 
         Serum sample from immunized cattle and controls were tested 
for antibody by indirect haemagglutination test. The highest titer was 
recorded in samples tested on day 24 post primary immunization. The 
antibody titer increased after boosting the animals. Results are shown 
in table 5 and fig 4. 
 
 
 46
Table (2). Results of indirect haemagglutination test of rabbit groups 
immunized with P. multocida cell lysate. 
Route of 
administration 
Rabbits
Day 
0 
Day 
7 
Day 
14 
Day 
21 
Day  
24 
Day 
31 
1 0 0 10 10 Booster 20 
1 0 0 10 20 Booster 40 
1 0 0 10 10 Booster 40 Intranasal 
Control 0 0 0 0 
N. 
Saline 
0 
1 0 10 10 20 Booster 40 
1 0 0 10 20 Booster 80 
1 0 10 20 40 Booster 160 Subcutaneous 
Control 0 0 0 0 
N. 
Saline 
0 
0
10
20
30
40
50
60
70
80
90
100
Ti
te
ra
tio
n
0 7 14 21 31
Days
FIG (2). Average of IHA of group of rabbits inoculation with cell lysate
I/N S/C  
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Table (3). Results of indirect haemagglutination test of rabbit groups 
inoculated with P. multocida toxoid. 
Route of 
administration 
Rabbits
Day 
0 
Day 
7 
Day 
14 
Day 
21 
Day 
24 
Day 
31 
1 0 0 10 20 Booster 40 
1 0 0 0 10 Booster 20 
1 0 0 10 10 Booster 40 Intranasal 
Control 0 0 0 0 
N. 
Saline 
0 
1 0 10 10 20 Booster 40 
1 0 0 20 40 Booster 160 
1 0 10 10 40 Booster 80 Subcutaneous 
Control 0 0 0 0 
N. 
Saline 
0 
0
10
20
30
40
50
60
70
80
90
100
Ti
te
ra
tio
n
0 7 14 21 31
Days
Fifg (3). Average of IHA of group of rabbits vaccinated with toxoid
I/N S/C  
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4.5.2. Group 2          
         The indirect heamagglutination test of nasal swab from 
vaccinated cattle and unvaccinated control group detected for mucosal 
antibodies. High titer was reported in samples taken on day 24 and 
after boosting animals (table 5). 
 
4.5.3. Group 3         
   Results of the indirect haemagglutination test for serum samples 
of cattle group immunized with bacterin are shown in table 5. The 
highest titer was obtained in samples taken at day 24 post vaccination. 
The antibody titer rised after the booster dose, see table 5 and fig 4. 
 
Table (4). Results of challenge inoculation in rabbits immunization 
groups. 
 
Vaccine 
Route of 
administration
No. of rabbits No. of dead No. of live 
Intranasal 3 0 3 
Bacterin 
Subcutaneous 3 0 3 
Intranasal 3 1 2 
Cell lysate 
Subcutaneous 3 0 3 
Intranasal 3 1 2 
Toxoid 
Subcutaneous 3 0 3 
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Table (5). Average results of indirect haemagglutination test of eight 
cattle vaccinated with P. multocida bacterin 
 
Route of 
administration 
Day 0 Day 7 Day 14 Day 21 Day 24 Day 31
I/N (0.5 ml) 0 3.75 5 7.5 11.25 20 
S/C (0.5 ml) 0 6.25 12.5 17.5 28.75 82.5 
S/C (1 ml) 0 8.75 12.5 21.25 36.25 92.5 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
Ti
te
ra
tio
n
0 7 14 21 24 31
Days
fig (4) Average of indirect haemagglutination test of three cattle groups (8 cattle each) 
vaccinated with P. multocida bacterin
I/N 0.5 ML S/C 0.5ML S/C 1 ML  
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Lesion 
 
Fig (5): Dermonecrotic activity of the partially purified P. multocida                            
            toxin 
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Fig (8): Indirect haemagglutination test in microtitre plate. 
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CHAPTER FIVE 
DISCUSSION 
 
         The present study was conducted to compare between efficacy of 
intranasal vaccination and subcutaneous vaccination in protecting 
rabbits and cattle against pneumonic pasteurellosis with  different 
vaccine preparations.                                                                    
         Mucosal adjuvants are importance in the delivery of vaccines to 
mucosal surface, these adjuvant should be non-irritant and have the 
minimal local side effect. In the study the Nigella sativa oil used as 
mucosal adjuvant was found toxic and lethal to rabbits when applied 
intranasally or subcutaneously. The exact mechanism of toxicity in 
rabbits remains to be clarified and no previous studies were reported in 
the literature describing the toxicity of N. sativa oil in rabbits.  
         Furthermore, a mixture Freund’s incomplete adjuvant and pea-
nut oil (1/1 v/v) was experimented was also were also as mucosal 
adjuvants in rabbits and no adverse reactions were reported, hence it 
was used in the present study to deliver the different vaccine 
preparations that included a bacterin, a toxoid and a cell lysate each of 
which was used to vaccinate groups of rabbits and cattle via the 
intranasal and subcutaneous route.          
         Filtrated culture supernatants of P. multocida injected 
intradermally in rabbits caused a local inflammation with no 
dermonecrosis, this finding in similar to the results reported by 
Dhanda, (1959). 
         Immunity in vaccinated animals was measured indirectly by 
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determination of the antibody titer using the indirect 
haemagglutination test and directly by challenge of vaccinated animal 
using viable P. multocida. 
         The bacterin vaccine was experimented in two groups of rabbits 
and it was administered intranasally and subcutaneously, using pea-
nut-freund’s incomplete adjuvant in both route. The indirect 
haemagglutination titers were greater in the subcutaneously inoculated 
group, compared with the titer of intranasally inoculated group. The 
lower titre recorded in the intranasally vaccinated groups might be the 
fact that the nasal lavage covered only small part of the respiratory 
mucosal surface hence the titre measured was not quantitative for the 
elicited mucosal immune response. The two vaccinated groups showed 
100% survival rate when challenged with 2.5x106 CFU/ml of P. 
multocida. And this result further substantiated that the intranasal 
vaccination affected protection in rabbits comparable to that elicited 
following subcutaneous vaccination. The results of bacterin 
vaccination in rabbits of the present study was in agreement with that 
reported by (Elbashir, 1993) who determined the immunogenic quality 
of the HS bacterin vaccine in group of rabbits administered through the 
subcutaneous route.  
         The antibody titer of the cell lysate vaccinated rabbit groups was 
higher in the subcutaneous route compared to the intranasal 
application, and might be explained as above of the bacterin. The 
survival rate of the two groups following challenge with 2.5x106 
CFU/ml was 100% for subcutaneous vaccinated group and 67% for 
intranasal vaccinated group. Results of this study clearly demonstrated 
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that cell lysate vaccine of P. multocida administered subcutaneous into 
rabbits were more efficient in eliciting antibody immune response and 
more protective against challenge exposure when compared to the 
same vaccine inoculated via the intranasal route.  
        In the toxoid vaccinated rabbit groups, the titers were greater in 
the subcutaneously inoculated group compared to the intranasally 
inoculated group. The survival rate of the groups following challenge 
with 2.5x106 CFU/ml was 100% and 67% for subcutaneously and 
intranasally vaccinated groups, respectively, indicating that the toxoid 
administered via the subcutaneous route affected better protection than 
that given intranasally. These results are partially consistent with the 
findings of Jarvinen et al., (1998) who vaccinated rabbits with a toxoid 
and potassium thiocyanate extract from cultures of P. multocida and 
demonstrated a 100 % protection in the two groups of rabbits 
immunized intranasally and subcutaneously.  
          The bacterin vaccine was experimented in two groups of cattle 
(each 10 cattle). via subcutaneous and intranasal routes with pea-nut 
plus Freund’s incomplete adjuvant. Results of indirect 
haemagglutination titers were greater in the subcutaneously inoculated 
group compared to intranasally immunized group.  
         The third group of cattle (10 cattle) which was immunized with 
1ml bacterin subcutaneously according to the program of vaccination 
of cattle against haemorrhagic septicaemia in the field. Showed 
indirect haemagglutination titers greater than the titres of group of 
cattle immunized via the intranasal route. This finding is in 
consistency with that of (Elbashir, 1993) who used a bacterin vaccine 
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produced in a continuous cultivation system. And such vaccines were 
shown to be antigenically superior to produced in static cultures.   
         In this study mucosal immunity to P. multocida resulted by 
vaccination with a bacterin, cell lysate and toxoid were in general less 
protective than subcutaneous route and this might be due to the fact 
that we used only one adjuvant necessitate in the future 
experimentation of other mucosal adjuvant which might confer better 
protection than the pea-nut-ferund’s incomplete adjuvant used in the 
present study.  
         Even though intranasal immunization with bacterin is an 
effective way to control infection, the method of vaccine delivery 
might be difficult to practice, especially when vaccinating a large 
number of animals. However, the efficacy of mucosal vaccination 
suggests that, it may eventually be possible to deliver these antigens by 
alternative routes, such orally, to induce mucosal immunity in 
respiratory tracts.   
         The titration of nasal swabs and nasal wash samples in cattle and 
rabbits respectively represents only small level titers because; the titers 
of the nasal samples may not represent the total respiratory tract 
surfaces, but despite this measurable antibody titre was detected.  
Nasal swabs are not a suitable technique for measuring secretary IgA, 
because the collection of nasal samples limited in nasal mucosa area of 
respiratory tracts. 
         In conclusion the study documented that P. multocida 
preparations administered to the local nasal mucosa elicited protective 
mucosal immune response. In addition results of the present 
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investigation showed that a mixture of ferund’s incomplete adjuvant 
and pea-nut oil demonstrated could act as a safe mucosal adjuvant to 
deliver antigens onto mucosal surfaces.  
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RECOMMENDATION 
 
 
According to results of the present study the following is 
recommended: 
• More studies on P. multocida should be conducted to 
experiment the delivery of vaccines via the intranasal rout 
rather than other routes.  
• Safe mucosal adjuvant should be explored to deliver P. 
multocida vaccines. 
• Design of new vaccine formulations that will be elicit 
protective immunity at mucosal surfaces. 
• More research should be done to test the efficacy of the 
current bacterin vaccine used to protect the national herd. 
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